» Articles » PMID: 35662932

Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?

Overview
Journal Front Nutr
Date 2022 Jun 6
PMID 35662932
Authors
Affiliations
Soon will be listed here.
Abstract

Despite continuous advances in pharmacotherapy, atherosclerotic cardiovascular disease remains the world's leading killer. Atherosclerosis relates not only to an increased level of cholesterol, but involves the development of atherosclerotic plaques, which are formed as a result of processes including inflammation and oxidative stress. Therefore, in addition to the classical risk factors for ASCVD (such as type 2 diabetes, overweight, obesity, hypertension and metabolic syndrome), residual risk factors such as inflammation and oxidative stress should also be reduced. The most important intervention in ASCVD is prevention, which includes promoting a healthy diet based on products of natural origin. Curcumin, which is often present in the diet, has been demonstrate to confer several benefits to health. It has been shown in numerous clinical trials that curcumin exhibited anti-diabetic, lipid-lowering, antihypertensive, antioxidant and anti-inflammatory effects, as well as promoting weight loss. All this means that curcumin has a comprehensive impact on the most important risk factors of ASCVD and may be a beneficial support in the treatment of these diseases. Recently, it has also been shown that curcumin may have a beneficial effect on the course of SARS-CoV-2 infection and might be helpful in the prevention of long-COVID complications. The aim of this review is to summarize the current knowledge regarding the safety and efficacy of curcumin in the prevention and treatment of cardiometabolic diseases.

Citing Articles

Impacts of Curcumin Supplementation on Cardiometabolic Risk Factors in Patients With Polycystic Ovary Syndrome: A Systematic Review and Dose-Response Meta-Analysis.

Mohammadi S, Ziaei S, Morvaridi M, Hasani M, Mirtaheri E, Farsi F Health Sci Rep. 2025; 8(3):e70525.

PMID: 40041784 PMC: 11872691. DOI: 10.1002/hsr2.70525.


Curcumin enhances ATG3-dependent autophagy and inhibits metastasis in cervical carcinoma.

Zheng F, Lu J, Wang C, Yu H, Fu Y, Ma D Cell Div. 2024; 19(1):33.

PMID: 39609925 PMC: 11606299. DOI: 10.1186/s13008-024-00138-6.


EF24, a Curcumin Analog, Reverses Interleukin-18-Induced miR-30a or miR-342-Dependent TRAF3IP2 Expression, RECK Suppression, and the Proinflammatory Phenotype of Human Aortic Smooth Muscle Cells.

Higashi Y, Dashek R, Delafontaine P, Rector R, Chandrasekar B Cells. 2024; 13(20.

PMID: 39451191 PMC: 11505909. DOI: 10.3390/cells13201673.


Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment.

Bertoncini-Silva C, Vlad A, Ricciarelli R, Giacomo Fassini P, Suen V, Zingg J Antioxidants (Basel). 2024; 13(3).

PMID: 38539864 PMC: 10967568. DOI: 10.3390/antiox13030331.


Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease.

Boldys A, Buldak L, Maliglowka M, Surma S, Okopien B Medicina (Kaunas). 2023; 59(10).

PMID: 37893507 PMC: 10608225. DOI: 10.3390/medicina59101789.


References
1.
Thota R, Acharya S, Garg M . Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial. Lipids Health Dis. 2019; 18(1):31. PMC: 6347796. DOI: 10.1186/s12944-019-0967-x. View

2.
Cheng A, Hsu C, Lin J, Hsu M, Ho Y, Shen T . Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21(4B):2895-900. View

3.
Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J . The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014; 58(3):516-27. DOI: 10.1002/mnfr.201300724. View

4.
Saadati S, Hatami B, Yari Z, Shahrbaf M, Eghtesad S, Mansour A . The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr. 2019; 73(3):441-449. DOI: 10.1038/s41430-018-0382-9. View

5.
Panahi Y, Hosseini M, Khalili N, Naimi E, Simental-Mendia L, Majeed M . Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed Pharmacother. 2016; 82:578-82. DOI: 10.1016/j.biopha.2016.05.037. View